Valeo Pharma Inc. News

Valeo Pharma to Present at the 2022 Bloom Burton & Co Healthcare Investor Conference

April 25, 2022 (Source) – Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical […]


Valeo Pharma Announces Listing of Convertible Debentures on TSX

April 19, 2022 (Source) – Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical […]


Valeo Pharma Announces Listing to the Toronto Stock Exchange

The Company’s shares and warrants to start trading on March 29th, 2022 March 28, 2022 (Source) — Valeo Pharma Inc. (TSX: VPH) (OTCQB: […]


Valeo Pharma Reports Its First Quarter 2022 Results and Highlights

Q1-22 revenues of $4.2 million, up 128% over Q1-21 Q1-22 gross margins of $1.4 million, up 266% over Q1-21 Public reimbursement secured […]


Valeo Pharma Secures Additional Public Reimbursement for Redesca™, Enerzair® Breezhaler® and Atectura® Breezhaler®

Canadian provincial public reimbursement now complete for Redesca with the addition of British Columbia Enerzair Breezhaler and Atectura Breezhaler reimbursement also […]


Valeo Pharma to Host First Quarter 2022 Results Conference Call / Webcast and Attend the 8th Annual AlphaNorth Capital Conference

March 17, 2022 (Source) – Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical […]